BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ZOLL Medical Corporation (ZOLL) Wins Patent Infringement Case Against ELan Med GmbH


3/11/2013 11:26:49 AM

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that the District Court of Munich, Germany, ruled in favor of ZOLL in granting an injunction against ELan Med GmbH of Cologne, Germany, for infringing on a ZOLL patent through the distribution and sale of certain ELan products for use with ZOLL’s Intravascular Temperature Management (IVTM™) systems. Under the terms of the judgment, ELan has been ordered to stop the manufacture and sale of infringing products for use with ZOLL’s patented temperature management systems (the Thermogard XP® and CoolGard 300® intravascular temperature management systems). The court also ruled that ZOLL is entitled to recover damages resulting from sales of the infringing products that were incurred since January 18, 2012, and ordered ELan to pay 90% of the cost of the court proceedings.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES